IAC 2008

A Smart + Strong Site
Subscribe to:
E-newsletters
POZ magazine
JOIN AIDSMEDS YouTube
XVII International AIDS Conference
IAC 2008 XVII International AIDS Conference
Mexico City, Mexico
August 3-8, 2008

Starting & Switching Treatment
August 6, 2008

Isentress Continues to Show Well Versus Sustiva as First-Line Treatment
New 96-week data from a clinical trial of Isentress (raltegravir), Merck's integrase inhibitor approved for treatment-experienced patients by the U.S. Food and Drug Administration in October 2007, suggest that it has comparable long-term efficacy to Sustiva (efavirenz) in those starting treatment for the first time. The new data, which also indicate fewer side effects with Isentress, were reported yesterday, August 5, at the XVII International AIDS Conference in Mexico City by Martin Markowitz, MD, of the Aaron Diamond AIDS Research Center in New York.


August 4, 2008

Similar Survival Among IDUs on ARV Treatment
HIV-positive injection drug users (IDUs) are just as likely to be alive 5 years after starting antiretroviral (ARV) therapy as non-IDU HIV-positive individuals, according to a report published in the August 6 issue of The Journal of the American Medical Association, coinciding with the start of the XVII International AIDS Conference in Mexico City. Julio Montaner, MD, of the University of British Columbia in Canada, and his study colleagues argue that these new data contradict the belief that IDUs with HIV receive fewer benefits from ARV therapy. 



Experimental HIV Drugs
August 12, 2008

Future Options for the Treatment Experienced
Andrew Carr, MD, Professor of Medicine at the University of New South Wales in Sydney, Australia, shares his views on the future of HIV treatment and what's in the pipeline for people with HIV who've been on many treatment regimens.


August 8, 2008

New NNRTI RDEA806 Shows Promise in Seven-Day Study
An experimental non-nucleoside reverse transcriptase inhibitor (NNRTI), currently dubbed RDEA806 by its developer Ardea Biosciences in San Diego, appeared to have robust antiviral activity and a favorable safety profile in a Phase II study reported at the XVII International AIDS Conference (IAC) in Mexico City. 



HIV Transmission & Prevention
August 14, 2008

New HIV Numbers: New Prevention Strategy? Part 1
The CDC's Kevin Fenton, MD, PhD, tells Regan Hofmann about the new HIV incidence report and the possibility of a national HIV strategic plan. Part 1 of 2



Featured Video

Global HIV/AIDS
August 19, 2008

AIDS Activism For The Next Decade
Mark Harrington, a long time AIDS activist and the Executive Director of the Treatment Action Group in New York City, predicts the coming challenges in AIDS activism and explains what people with HIV and their allies can do about them.


August 15, 2008

Human Rights Struggles Define AIDS Fight
Harvard's Sofia Gruskin, JD, MIA, associate professor of health and human rights, talks about the impact of human rights struggles on the AIDS epidemic, progress finally being made, and the legacy of Dr. Jonathan Mann.



HIV/AIDS Complications

Regan's Blog
August 6, 2008

La Voz Global
Today, POZ made the backpage of La Voz Global, the daily newspaper of the International AIDS Conference! We have a space in the Global Village where we are collecting photographs and videos of people living with, and those affected by, HIV from around the world.

August 3, 2008

Bienvenidos a AIDS 2008!
Good morning from incredibly beautiful Mexico City, the site of the XVII International AIDS Conference (IAC)! The sprawling metropolis is verdant and covered in candy-colored roses.


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.